Phase 2 Stroke Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People aged 18 to 85 years old, of any gender
• People who have been diagnosed with an acute ischemic stroke (a stroke caused by a blocked blood vessel in the brain) according to 2023 Chinese stroke diagnosis guidelines
• People whose stroke symptoms began no more than 24 hours ago (if the exact time is unknown — for example, if the stroke happened during sleep — the last time the person was known to be well is used as the starting point)
• People who were largely independent in daily life before the stroke, with little to no disability (a score of 0 or 1 on a standard disability scale called the modified Rankin Scale)
• People whose stroke symptoms fall within a moderate severity range on a standard stroke assessment scale (NIHSS score between 6 and 20), and who have measurable weakness in both an arm and a leg
• People who are planned to receive, or have already received, clot-dissolving treatment (thrombolysis) for their stroke
• Women of childbearing potential who have a negative pregnancy test and report no sexual activity in the 14 days before joining the study, and all people of childbearing potential (male or female) who agree not to plan a pregnancy or donate sperm during the study and are willing to use at least one reliable form of contraception
• People (or their legal guardian) who are willing and able to provide signed consent to participate

Who may not be able to join:

• People with a known allergy to any ingredient in the study drug (QD202) or its placebo
• People whose brain scan shows any bleeding in the brain, such as a bleed around or within the brain — though people with only very small, minor bleeds (microbleeds) or bleeding that occurs as a complication of clot-dissolving treatment may be considered at the trial doctor's discretion
• People whose stroke turns out to be a transient ischemic attack (TIA), sometimes called a "mini-stroke," where symptoms resolve quickly
• People with poorly controlled blood pressure despite active treatment — either very high (top number at or above 220 or bottom number at or above 120 mmHg) or very low (top number at or below 90 or bottom number at or below 40 mmHg)
• People with severely abnormal blood sugar levels — either very high (at or above 400 mg/dL) or very low (at or below 50 mg/dL)
• People with a heart rate that is too slow (below 50 beats per minute) or too fast (above 120 beats per minute), certain types of heart rhythm problems, or a history within the past 6 months of serious heart conditions including severe heart failure, unstable chest pain, heart attack, or serious irregular heartbeat
• People who are deeply unconscious or very severely unresponsive at the time of assessment before clot-dissolving treatment (a score of 2 or higher on the consciousness section of the stroke severity scale)
• People with a history of severe mental illness or severe dementia
• People with a history of depression or anxiety, if the trial doctor considers participation to be inappropriate
• People who are not suitable for clot-dissolving treatment, or who have had or are planned to have a procedure to physically remove or break up the clot inside a blood vessel (endovascular therapy)
• People who have taken certain brain-protective medications after the stroke began, including a specific list of named drugs (confirm with trial site for the full list) — mannitol used to lower pressure in the brain is an exception and is permitted
• People who have been diagnosed with cancer and are currently receiving anti-cancer treatment
• People with a serious ongoing medical condition where life expectancy is estimated to be less than 90 days
• People with severe active liver disease (such as hepatitis or cirrhosis) or abnormal liver blood test results more than twice the normal upper limit
• People with severe active kidney disease or significantly reduced kidney function (eGFR below 60 mL/min/1.73 m²)
• People with a tendency to bleed, including a low platelet count (below 75.0×10⁹/L), or a history of major bleeding in the 3 months before the stroke
• People who have had major surgery within 4 weeks before joining the study, if the trial doctor believes this could affect the study assessments or the person's survival over 90 days
• People with alcohol dependence, drug abuse, or substance addiction
• People who have taken part in another clinical trial involving an experimental drug, vaccine, or medical device within the past 3 months
• People who cannot safely have a CT or MRI scan, for example due to a pacemaker, certain metal implants, or severe claustrophobia
• People with an allergy to contrast dye used in medical scans
• People with chronic moderate to severe lung or breathing disease
• People who are pregnant or breastfeeding
• People whom the trial doctor considers unsuitable for any other reason

Important: Always verify eligibility with the trial site directly before applying.